公开(公告)号：US20240009196A1

公开(公告)日：2024-01-11

申请号：US18162955

申请日：2023-02-01

Applicant: MORPHOSYS AG

Inventor： Jan ENDELL ,  Rainer BOXHAMMER ,  Mark WINDERLICH

IPC: A61K31/519 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K39/3955 ,  C07K16/2803 ,  A61P35/00 ,  A61K2039/505

Abstract: The present disclsoure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

公开(公告)号：US20220242952A1

公开(公告)日：2022-08-04

申请号：US17605285

申请日：2020-05-04

Applicant: MORPHOSYS AG

Inventor： Christian KUFFER ,  Guenter FINGERLE-ROWSON ,  Mark WINDERLICH ,  Jan ENDELL

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574). Furthermore, the present application relates to anti-CD19 antibodies for the treatment of leukemia or lymphoma in patients having a peripheral NK cell count at baseline of less or equal to 100 NK cells/μl

公开(公告)号：US20200206228A1

公开(公告)日：2020-07-02

申请号：US16806353

申请日：2020-03-02

Applicant: MORPHOSYS AG

Inventor： Jan ENDELL ,  Rainer BOXHAMMER ,  Mark WINDERLICH

IPC: A61K31/519 ,  C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K39/395

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

公开(公告)号：US20220088197A1

公开(公告)日：2022-03-24

申请号：US17545274

申请日：2021-12-08

Applicant: MorphoSys AG

Inventor： Jan ENDELL ,  Mark WINDERLICH ,  Rainer BOXHAMMER

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/02 ,  C07D403/12 ,  C07D473/16

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

公开(公告)号：US20220283166A1

公开(公告)日：2022-09-08

申请号：US17824266

申请日：2022-05-25

Applicant: MORPHOSYS AG

Inventor： Jan ENDELL ,  Mark WINDERLICH ,  Rainer BOXHAMMER

IPC: G01N33/574 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28

Abstract: The present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with an anti-CD19 antibody.